Abstract
The process of blood vessel proliferation, known as angiogenesis, is essential during embryonic development and organogenesis. In adult life, it participates in normal tissue repair, wound healing, and cyclical growth of the corpus luteum and the endometrium. Crucial as it is, angiogenesis can become pathological, and abnormal angiogenesis contributes to the pathogenesis of inflammatory and neoplasic diseases. The present review highlights the evidence for the role of angiogenesis in HCC (hepatocellular carcinoma) and discusses the increasing importance of inhibitors of angiogenesis in HCC therapy.
MeSH terms
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Hepatocellular / blood supply*
-
Carcinoma, Hepatocellular / drug therapy
-
Carcinoma, Hepatocellular / metabolism
-
Humans
-
Liver Neoplasms / blood supply*
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / metabolism
-
Neoplasm Proteins / metabolism
-
Neovascularization, Pathologic / drug therapy*
-
Receptors, Vascular Endothelial Growth Factor / metabolism
-
Vascular Endothelial Growth Factors / metabolism
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Neoplasm Proteins
-
Vascular Endothelial Growth Factors
-
Receptors, Vascular Endothelial Growth Factor